pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Drugs
by stage
  • Marketed
  • Phase 3
  • Phase 2
  • Phase 1
  • Preclinical
browse
  • Most catalysts
  • Recently active
  • All drugs →
  • Companies
  • Patent cliff
Calendar
what
  • Trial readouts
  • PDUFA dates
  • Approvals
  • Earnings
when
  • Upcoming
  • Month grid
  • Recently passed
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
  • Drugs
  • Calendar
  • Companies
Hubs
  • Topics
  • Patent cliff
  • Publications
  • Readouts
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
PUBLIC COMPANY
save

$ONCBeOne Medicines Ltd.

$ONC411.29-1.26%
Basel, CHupdated 14h ago

BeOne Medicines, formerly known as BeiGene, Ltd. is a multinational oncology company. It specializes in the development of drugs for cancer treatment.

Website ↗SEC EDGAR ↗Yahoo Finance ↗
community read0 votes

🐶 often sniffed alongside

top 7
  • tagOncology10 co-mentions · 2 sources
  • company$BEIGFBeOne Medicines Ltd.2 co-mentions · 2 sources
  • tagNSCLC2 co-mentions · 1 sources
  • tagPulmonology1 co-mentions · 1 sources
  • tagHepatology1 co-mentions · 1 sources
  • drugBG-898941 co-mentions · 1 sources
  • drugBGC-09791 co-mentions · 1 sources
pipeline
8
marketed
1
phase 3
1
catalysts ytd
5
approvals ytd
0
recalls ytd
0

Pipeline(8)

pipeline depth8 products
Phase 1: 1Phase 2: 2Phase 3: 1Marketed: 1Unknown: 2pre_registration: 1
1Phase 12Phase 21Phase 31Marketed2Unknown1pre_registration
Marketed
zanubrutinib
Membranous Glomerulonephritis
Tyrosine-protein kinase BTK
Phase 3
Tevimbra
Small-Cell Lung Cancer
Programmed cell death protein 1
Phase 2
BGB-16673
Refractory Chronic Lymphocytic Leukemia (CLL)
Phase 2
surzebiclimab
Recurrent Head And Neck Squamous Cell Carcinoma
Phase 1
BGBB-2033
Metastatic Hepatocellular Carcinoma (HCC)
drug
BG-89894
drug
BGC-0979
pre_registration
sonrotoclax
Mantle Cell Lymphoma

📅 Upcoming

no upcoming catalysts on record

🕒 Recent(90d)

earnings (1)
Nov 5, 2026
earnings
$ONC411.29-1.26%
12d ago
BeOne Medicines Ltd. earnings
BeOne Medicines Ltd.
→
view all catalysts →
🐶 Hiring Signal
No open roles indexed yet — view BeOne Medicines Ltd. jobs →

News

  • BeOne, Hengrui top list of China’s most powerful drugmakers
    A new STAT-WireScreen index ranks China's most valuable publicly traded biotech companies. See which one topped the list.
    stat · 1d ago
  • China has a clear shot to 2030 goals, though economic, cultural barriers remain
    To grow into a biopharma juggernaut, China aims to become the leading source of innovative medicines on the global markets—a goal that experts say the country is on track to hit.
    biospace · 6d ago
  • Could we see 10 Chinese Big Pharmas within a decade? Some CEOs think so
    For executives at many of the Chinese drug developers who spoke to Fierce, the real prize is a seat at the Big Pharma table. In recent years, this objective has moved from a vague aspiration to a c…
    fiercebiotech · 10d ago
  • RevMed’s Rasonque shatters analyst estimates with $198M quarter
    Pent-up demand for the new pancreatic cancer therapy Rasonque helped RevMed soar past analysts’ sales expectations and reach 5,000 patients in the third quarter.
    biospace · 11d ago
  • With MFN now embedded in pharma, execs see little impact from Democrats’ blue wave
    Speaking on third quarter earnings calls this week, Novo and Pfizer’s CEOs see little change to their Most Favored Nation drug pricing deals, which were signed with the Trump administration last year.
    biospace · 12d ago
  • 6 potential blockbusters that could pave China’s path to 2030 ambitions
    In its latest five-year plan, China has set its sights on developing five drugs that could each rake in more than $1 billion globally by 2030. Experts say it's well on its way, with two medications…
    biospace · 13d ago
  • Nurix drops one BTK degrader as momentum builds behind Roche-partnered option
    Nurix’s BTK degrader zelebrudomide may have survived a clinical hold in recent years, but that hasn’t stopped the California biotech from dropping the cancer drug.
    fiercebiotech · 1mo ago
  • 5 biggest venture capital raises of Q3 2026
    Venture capital continued to flow into biopharma in the third quarter, though experts pointed out that investors remained selective, preferring to put their money behind advanced and derisked asset…
    biospace · 1mo ago
  • DPHARM: How to address the clinical trial enrollment crisis?
    Clinical trials are facing an enrollment crisis. Around 80% of trials don’t meet their enrollment timelines, and fewer than 5% of eligible adult cancer patients participate in trials.
    fiercebiotech · 2mo ago
  • Drugmakers cherry pick launch regions as MFN creates 'policy environment like an earthquake'
    With multiple drug pricing initiatives like Most Favored Nation now in force, drugmakers have to reinvent their commercial strategies to stay ahead of the fast-moving policy environment, according…
    biospace · 2mo ago
view all news mentions →
identifiers
ticker
$ONC
SEC CIK
0001651308
country
CH
source
sec_tickers
top tags
Oncology6NSCLC1
mentioned in
10news items
entity-linker matched
Data sources
SEC EDGAR · openFDA
last refreshed 40m ago
Found something off?
🐶 something off?

Report a data issue

Tell Bork what looks wrong — wrong sponsor, stale phase, mislinked ticker, anything. We’ll triage and fix.

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?